A Safety and Efficacy Study of Oral Tapentadol Extended-Release in Japanese Participants
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the conversion rate based on the number of
participants achieving pain control and safety within 1 week after switching the opioid
(morphine-like medications) analgesics (drug used to control pain), when tapentadol
extended-release (ER) (JNS024ER) is orally administered to participants treated with
around-the-clock opioid analgesics, for their moderate to severe (very serious, life
threatening) chronic (lasting a long time) malignant (cancerous) tumor-related (a mass in a
specific area) cancer (abnormal tissue that grows and spreads in the body) pain.